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mTOR/S6K pathway is a crucial regulator of cell growth and metabolism. Deregulated signalling via S6K has been linked to
various human pathologies, including metabolic disorders and cancer. Many of the molecules signalling upstream of S6K have
been shown to be either mutated or overexpressed in tumours, leading to S6K activation. The role of S6K1 in brain tumours is
not fully investigated. In this study, we investigated the gene expression proﬁle of S6 kinases in brain and CNS tumours using the
publically available Cancer Microarray Database. We found that S6K1 but not S6K2 gene is overexpressed in brain tumours and
this upregulation is associated with patients’ poor survival. Furthermore, we interrogated Oncomine database for the expression
proﬁle of hypoxia-induced genes using a literature-deﬁned concept. This gene list included HIF1A, VEGFA, SOX4, SOX9, MMP2,
and NEDD9. We show that those genes are upregulated in all brain tumour studies investigated. Additionally, we analysed the
coexpression proﬁle of S6K1 and hypoxia responsive genes. The analysis was done across 4 diﬀerent brain studies and showed that
S6K1 is co-overexpressed with several hypoxia responsive genes. This study highlights the possible role of S6K1 in brain tumour
progression and prediction of patients’ survival. However, new epidemiological studies should be conducted in order to conﬁrm
these associations and to reﬁne the role of S6K1 in brain tumours as a useful marker for patients’ survival.
1.Introduction
Brain and other central nervous system (CNS) cancers
include a variety of histopathologic subtypes, but the
most common, by far, are gliomas. These tumours, which
arise from the glial cells that surround and support neu-
rons,includeastrocytoma,glioblastoma,oligodendroglioma,
oligoastrocytoma, and ependymoma. Medulloblastoma,
another neuroepithelial cancer, is relatively common in
childrenbutrareinadults.Braincancersinchildrentypically
arise in the cerebellum, whereas brain cancers in adults are
more likely to occur in the cerebral hemispheres [1]. In
adults, older age at diagnosis of brain cancer is associated
with higher tumour grade and poorer prognosis. Indeed,
glioblastoma is among the most lethal of all cancers. Brain
and central nervous system (CNS) tumours occur at each
stage of life and are therefore classiﬁed as embryonic, pae-
diatric, and adult cancers [2, 3].
According to Central Brain Tumour Registry of the
Unites States (CBTRUS), the prevalence rate for all primary
brain and central nervous system tumours was estimated
to be 209.0 per 100,000 in 2004 [4]. The ﬁve-year relative
survival rate following diagnosis of a primary malignant
brain and central nervous system tumour is 33.8% for males
and 37.5% for females (1995–2007 data) [5]. In Egypt, brain
and other CNS cancers accounted for 3.1% of all cancers in
Egyptians, a large majority of cancers were located in the
brain (85.2%) (Middle East Cancer Consortium 1995–2001)
[6].
Due to the lack of eﬀective therapies for aggressive brain
and CNS tumours, the identiﬁcation of new targets and
prognostic indicators is required. Current studies in this area
are focused on developing new therapies that target speciﬁc
molecular events that lead to malignant transformation of
cells [7].2 Journal of Oncology
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Figure 1: S6K1 is overexpressed in brain tumours in Oncomine database. Data sets in a single panel were from the same study. Gene
expression proﬁle of S6K1 gene (GEP) data are log transformed and normalized as previously described [26]. In brackets, are indicated the
number of patients in each category. (a) Comparison between S6K1 gene expression in brain tumours against normal counterparts. (b)
Comparison between S6K1 gene expression in diﬀerent histopathological types of brain tumours.
The PI3K/Akt pathway is one of the major cell sur-
vival pathways activated on stimulation of receptor tyro-
sine kinases such as epidermal growth factor receptors
(EGFR) that are over expressed in 40–60% of gliomas [8–
10]. Activation of PI3K/Akt pathway has been associated
with malignant transformation of cells and is frequently
overexpressed in glioblastoma tumours when compared to
nonglioblastoma tumours [11]. This activation is also asso-
ciated with increased tumour grade that correlates positively
with adverse clinical outcome in gliomas [12]. Mammalian
targetofrapamycin(mTOR)isaserine/threoninekinasethat
functions downstream of the PI3K/Akt pathway [13]. mTOR
is known to regulate cell proliferation, growth, and survival
by regulating translation initiation. Akt is shown to activate
mTOR through inhibition of TSC1/2 (tuberous sclerosis
complex 1 and 2) and activation of Ras homologue-enriched
in brain (Rheb) [14]. Upon activation by mTOR, S6K1
phosphorylates S6 ribosomal protein, leading to increased
translation of mRNA with oligopyrimidine tract at the 5 
terminal (5 TOP) [15].
S6K1 itself has no speciﬁc inhibitors that are available
commercially but it responds to inhibitors that target
its upstream regulators as mTOR and PI3K. Rapamycin
(sirolimus), a macrolide antibiotic, blocks mTOR kinase
activity by forming a complex with FK506-binding protein
(FKBP-12), thereby leading to the blockade of translation
initiation through its action on S6K and 4EBP1 and cell
cycle arrest at G1 phase [16, 17]. Rapamycin’s growth
inhibitory action has also been correlated with a decrease
in glucose and amino acids uptake by rapamycin-sensitive
glioblastoma cells [18]. Several clinical trials of rapamycin
and its derivatives are being conducted to evaluate their
eﬃcacy [19]. Rapamycin and its derivatives have been shown
to inhibit growth in several cancers, including breast cancer,
pancreatic cancer, prostate cancer, melanoma, renal cell
cancer, leukemia, and glioblastoma [20–22]. Phase II trial
with temsirolimus, an ester analog of rapamycin, showed
that this drug was well tolerated in patients with recurrent
glioblastomaandthisstudyhasalsoshownthatpatientswith
high baseline levels of S6K1 responded to the drug treatment
[23].
Using human glioma cell lines and transformed human
astrocytes, Nakamura et al., 2008, have found that sup-
pression of mTOR or raptor was suﬃcient to signiﬁcantly
reduce anchorage-independent growth in soft agar, an
assay of transformation. Furthermore, S6K1, but not eIF4E,
rescued glioma growth in soft agar from rapamycin-me-
diated suppression, and transient S6K1 inhibition was suf-
ﬁcient to signiﬁcantly reduce glioma growth in soft agar.
Additionally, they found that in vivo S6K1 suppression in
intracranially implanted glioma xenografts reduced levels of
phosphorylated S6 and also resulted in reduced intracranialJournal of Oncology 3
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Figure 2: S6K1 gene overexpression in brain tumours compared to normal brain is associated with patients’ poor survival. Data sets in a
single panel were from the same study. Gene expression proﬁle [GEP] data are log transformed and normalized as previously described [26].
In brackets, are indicated the number of samples. (a) Comparison of S6K1 gene expression proﬁle in brain tumours French Brain Study [27]
compared to normal brain. (b) Comparison of S6K1 gene expression proﬁle in brain tumours in both alive and dead subjects at 3 and 5 years
of survival.
tumour growth. Their ﬁndings deﬁne a signiﬁcant role for
the mTOR-raptor (mTORC1)-S6K pathway in supporting
gliomagenesis [24].
The ribosomal protein S6 kinase (S6K) family is a key
regulator of cell growth and cell size and acts downstream of
thePI3K/mTORpathway,andithasbeenidentiﬁedtodateto
exert crucial functions in many other cellular processes such
as metabolism and transcription regulation. The importance
of the PI3K and mTOR pathways in the regulation of
S6K activity was revealed by the ability of inhibitors of
those pathways to block the activity of S6 kinases. Acti-
vating mutations in kinases involved in signalling via the
PI3K/mTOR/S6K pathway were identiﬁed in many tumours
indicating the oncogenic nature of this signalling pathway.
On the other hand, inhibitory mechanisms were described
to target S6K pathway through inhibiting its upstream
signalling. Inhibitory mechanisms are exerted by a number
of tumour suppressor genes such as PTEN, TSC1/2, REDD1,
and others. Deregulation of those proteins in many tumours
has resulted in activation of PI3K and mTOR pathways and
in turn to S6K activation. This has raised the possibility
that S6 kinases are involved in tumour progression processes
(reviewed in [25]).
The initial link between mTOR/S6K regulation and the
cellular response to hypoxia has come from several studies,
which have demonstrated that mTOR signalling upregulates
expression of the hypoxia inducible factor (HIF-1α)a n d
vascular endothelial growth factor (VEGF), reviewed in [30].
Recently, a TOS motif has been found in HIF-1α subunit,
which also binds to raptor [31]. Loss of the TOS motif
disrupts regulation of hypoxia via HIF-1α. Immunoﬂuo-
rescent analysis of S6K1 and AKT phosphorylation status
has revealed positive correlation between a high p-Akt and
p-S6K expression, and a venous and capsular invasion of
hepatocellular carcinoma (HCC) [32]. This suggests that
activation of the Akt-mTOR-S6K pathway plays a signiﬁcant
role in HCC progression by promoting neoangiogenesis.
A proposed model for the inhibition of mTOR/S6K
pathway occurs underhypoxic conditions through coordina-
tion of diﬀerent upstream tumour suppressors. This model
involves three diﬀerent mechanisms: (1) REDD1 upregu-
lation, (2) AMPK activation resulting in mTOR inhibition
through the activation of the TSC1/TSC2 tumour suppressor
complex [33, 34], and (3) mTOR accumulation in the
nucleus through the action of the PML tumour suppressor
[35]. All three regulatory events inhibit the interaction of
mTOR with Rheb, which in turn reduces the phosphoryla-
tion/activationofS6K.InhibitionofthemTOR/S6Kpathway
through these mechanisms results in decreased translation
of HIF-1α and expression of VEGF [33–35]. Deregulation
of these tumour suppressors in cancer results in activation
of the mTOR/S6K pathway and subsequent elevation of
HIF-1α and VEGF, which promote tumour angiogenesis.
The combination of mTOR inhibitors with angiogenesis
inhibitors could be a useful tool for cancer therapy.4 Journal of Oncology
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Figure 3: S6K1 gene is coexpressed with hypoxia responsive genes in oncomine database. (a) Heat map of coexpression proﬁle of S6K1
and hypoxia induced genes in atypical teratoid tumours compared with normal cerebellum Pomeroy brain study [28]. (b) Comparison of
co-expression gene proﬁle of S6K1 and hypoxia induced genes across 4 diﬀerent analyses [27–29].Journal of Oncology 5
In this study, we aimed to investigate the gene expression
proﬁle of S6 kinases in human brain tumours and its
association with patients’ clinical outcomes as response
to treatment, recurrence, and survival. Additionally, we
performed coexpression analysis of S6 kinases and hypoxia-
induced genes. We performed those analysis using publically
available cancer microarray database; ONCOMINE.
2.MaterialsandMethods
2.1. Databases. We used Oncomine Cancer Microarray da-
tabase (http://www.oncomine.org/)[ 26] to study the proﬁle
of S6K1, S6K2, and hypoxia-induced genes expression in
human brain and CNS tumour types versus their normal
tissue counterparts. In order to compare the gene expression
in a tumour type to its normal counterpart, gene expres-
sion data from a same study, performed with the same
methodology, were used. The gene expression data were log
transformed, median centered per array, and the standard
deviation was normalized to one per array [26]. A gene was
considered as overexpressed when its mean value in tumour
samples was signiﬁcantly higher to its mean value in the
normal tissue counterpart using a t-test (P ≤ 0.05) and the
fold of induction was ≥1.5. Brain and CNS cancer data sets
used in this study are summarised in Table 1.
2.2. Statistical Analysis. The results were analysed using
GraphPad prism computer system (GraphPad Software, San
Diego, USA). Statistical analysis comparisons were done
with Mann-Whitney or student t-tests for gene expression
analysis.
3. Results
3.1. S6 Kinase 1 Is Overexpressed in Human Brain Tumours.
In the present study, we queried the Oncomine database
to systematically assess relative gene expression levels of
S6K1 and S6K2 genes in brain and CNS tumours. Gene
expression data from embryonic, pediatric, and adult
brain tumours were collected from Oncomine database
(http://www.oncomine.com/)[ 26]. We compared gene
expression in normal brain versus cancer tissues, and
in diﬀerent histological subtypes. Diﬀerential analysis of
S6 kinases gene expression in brain and CNS tumours
versus normal tissue counterparts has retrieved 9 results
in Oncomine database. We have analysed the studies that
showed a signiﬁcant diﬀerence value of gene expression (P ≤
0.05) in cancerous tissues compared with normal counter-
parts. S6K1 gene (RPS6KB1) is signiﬁcantly overexpressed
in diﬀerent brain tumours compared with normal brain
tissue in 4 independent studies. On the other hand, S6K2
(RPS6KB2) gene expression proﬁle did not change between
cancerous and normal brain tissues (data not shown). S6K1
gene expression is signiﬁcantly upregulated in Pomeroy et al.
study [28] that analysed four diﬀerent tumour types against
normal cerebellum; atypical teratoid/rhabdoid tumour (fold
= 20.023, P = 0.015), classic medulloblastoma (fold =
13.827, P = 0.02), desmoplastic medulloblastoma (fold =
6.658, P = 0.05), and malignant glioma (fold = 5.389, P =
0.06). While in Sun et al. study [36], S6K1 is overexpressed
in glioblastoma compared to normal brain (fold = 1.57, P =
4.21E − 11), and in anaplastic astrocytoma (fold = 1.5,
P = 4.72E − 5). Furthermore, we have found that S6K1 is
overexpressed in glioblastoma compared to normal brain in
a Murat brain study, 2008 [43]( f o l d= 1.644, P = 9.89E−4).
Figure 1(a) shows some representative results of the analysis
performed of S6K1 in brain tumours against normal brain.
Furthermore, we have found that S6K1 is diﬀerentially
overexpressed in speciﬁc histology types of brain tumours.
In van den Boom et al. study [42], S6K1 gene is diﬀer-
entially overexpressed in mixed glioma when compared to
astrocytoma and glioblastoma (P = 0.017). While in Nutt
et al. study [29], S6K1 is diﬀerentially overexpressed in
glioblastoma against oligodendroglial tumour (P = 0.002).
(Figure 1(b)).
These results indicate that S6K1 gene but not S6K2 is
overexpressed in a number of brain and CNS tumours and
shows diﬀerential expression proﬁle in speciﬁc histological
types.
3.2. S6K1 Overexpression Is Associated with Patients’ Poor
Survival. To assess the clinical signiﬁcance of S6K1 overex-
pression in brain tumours, we investigated the association
between its gene expression levels and the patient’s clinical
outcome including response to treatment, recurrence, and
survival status. No signiﬁcant association between S6K1
gene expression levels and patients response to therapy or
sample recurrence status was identiﬁed, while a signiﬁ-
cant association between S6K1 overexpression and patients’
poor survival status was observed. In French et al. study
[27], S6K1 gene is signiﬁcantly overexpressed in anaplastic
oligoastrocytoma compared to normal brain (P = 5.20E−4)
and in anaplastic oligodendroglioma compared to normal
brain (P = 0.0045, Figure 2(a)). In the same study, as
shown in Figure 2(b), S6K1 is signiﬁcantly overexpressed
in patients who died later after 3 and 5 years of diagnosis
(P = 0.007 and P = 0.018, resp.). Additionally, we found
that S6K1 is overexpressed in patients who died after 5
years of surgical resection compared to alive patients (P =
0.0136) [27]. Furthermore, we have tested the association
between S6K1 gene expression and patients’ survival by
analysing the data available from Pomeroy et al. study
[28]. We have found that, in classic medulloblastoma, S6K1
overexpression is signiﬁcantly associated with patients’ poor
survival (P = 0.04) (supplementary Figure 1(a) available at
doi:10.1155/2012/416927).
Taken together, we conclude that S6K1 is overexpressed
in patients that showed poor survival status. This indicates
that S6K1 gene expression could be used as a useful marker
to predict patients’ survival.
3.3. Hypoxia Induced Genes Are Overexpressed in Human
Brain Tumours. The adaptation of tumours to hypoxia is
critical for their survival and growth. The high proliferation
rate of solid tumours causes the continuous outstripping of
theoxygensupplyprovidedbythelocalvasculature,resulting6 Journal of Oncology
Table 1: Oncomine studies used in this analysis.
Study Sample type Patients’
numbers Year of the study REF
Sun Brain
Normal brain
Oligodendroglioma
Anaplastic astrocytoma
Glioblastoma
Diﬀuse astrocytoma
23
50
19
81
7
2006 [36]
Shai Brain Glioblastoma
Normal white matter7
27
7 2003 [37]
Rickman Brain Astrocytoma
Normal temporal Lobe
45
6 2001 [38]
French Brain
Normal brain
Anaplastic oligoastrocytoma
Anaplastic oligodendroglioma
6
4
23
2006 [27]
Bredel Brain 2
Glioblastoma
Oligodendroglioma
Anaplastic oligodendroglioma
Anaplastic oligoastrocytoma
Normal brain
27
5
3
6
4
2005 [39]
Liang Brain
Glioblastoma
Oligoastrocytoma
Oligodendroglioma
Normal brain
Normal cerebellum
29
3
2
2
1
2005 [40]
Gutmann Brain Pilocytic astrocytoma
Normal white matter
8
3 2002 [41]
Pomeroy Brain
Atypical teratoid/rhabdoid tumour
Classic medulloblastoma
Desmoplastic medulloblastoma
Malignant glioma, NOS
Primitive neuroectodermal tumour, NOS
Normal Brain
5
46
14
10
6
4
2002 [28]
Nutt Brain Anaplastic oligodendroglioma
Glioblastoma
22
28 2003 [29]
Van den Boom Brain
Glioblastoma
Mixed glioma
Astrocytoma
4
4
8
2003 [42]
Murat Brain Glioblastoma 80 2008 [43]
Total 622
in hypoxic regions within the tumour. Hypoxia inducible
factor (HIF) is the key mediator of cellular response to
hypoxia, activating the expression of multiple genes that par-
ticipate in angiogenesis, iron metabolism, glycolysis, glucose
transport, and cell proliferation and survival. To assess the
gene expression proﬁle of hypoxia-induced genes in brain
andCNStumours,wequeriedtheoncominedatabaseforthe
following genes; HIF1A1, VEGFA, MMP2, NEDD9, SOX4,
and SOX9. Those genes were selected based on literature.
We found that hypoxia-induced genes are overexpressed in
a number of brain tumours.
Table 2 summarizes the analysis results of the selected
genes indicating the induction fold and the signiﬁcance
diﬀerence of gene expression in a tumour type compare to
normal brain. Only analysis that showed fold of induction
>2a n dP < 0.01 was included. The results we show here
highlights the importance of hypoxic mechanism in brain
tumours and the high level of overexpression of angiogenic
factors as HIF1A, VEGFA, and MMP2 that are implicated in
metastasis could be target molecules in those tumour types.
3.4. S6K1 Is Coexpressed with Genes Induced by Hypoxia.
S6K1 regulates cell size and metabolism. Only recently, a
connection between mTOR/S6K pathways to hypoxia was
suggested by diﬀerent studies. Here, we aimed to investigate
the coexpression proﬁle of S6K1 and hypoxia-induced genes
in brain tumours. To achieve that, we queried the oncomine
database using a literature deﬁned concept “Concept: Upreg-
ulated genes in response to hypoxia and in response to
HIF-1 expression.” This concept included a gene list of
genes reported in literature to be upregulated by hypoxiaJournal of Oncology 7
Table 2: Hypoxia induced genes are overexpressed in human brain tumours.
Gene Brain tumour type Upregulation fold/normal P Value Patients’ number Study/year [REF]
SOX4
Oligodendroglioma 27.195 P = 7.16E −22 50
Nutt Brain/2006 [36] Anaplastic astrocytoma 22.784 P = 1.96E −13 19
Glioblastoma 4.149 P = 1.06E −21 81
Diﬀuse astrocytoma 9.109 P = 0.007 7
Glioblastoma 3.084 P = 8.51E −8 27 Shai Brain/2003 [37]
Astrocytoma 6.100 P = 1.65E −5 45 Rickman Brain/2001 [38]
Anaplastic oligoastrocytoma 17.598 P = 6.05E −54
French Brain/2005 [27]
Anaplastic oligodendroglioma 2.790 P = 4.62E −82 3
Glioblastoma 6.140 P = 2.76E −92 7
Bredel Brain 2/2005 [39] Oligodendroglioma 12.935 P = 2.22E −45
Anaplastic oligodendroglioma 15.078 P = 0.002 3
Anaplastic oligoastrocytoma 8.939 P = 0.006 6
Glioblastoma 4.579 P = 2.20E −42 9 Liang Brain/2005 [40]
Oligoastrocytoma 7.482 P = 0.009 3
Pilocytic astrocytoma 3.445 P = 0.008 8 Gutmann Brain/2002 [41]
SOX9
Malignant glioma 4.330 P = 9.30E −61 0
Pomeroy Brain/2002 [28] Atypical teratoid/rhabdoid tumour 3.668 P = 0.007 5
Desmoplastic medulloblastoma 2.599 P = 0.002 14
Anaplastic oligoastrocytoma 4.005 P = 0.009 23 French Brain/2005 [27]
Anaplastic oligodendroglioma 2.731 P = 3.03E −44
Glioblastoma 2.566 P = 2.84E −5 27 Shai Brain/2003 [37]
Anaplastic astrocytoma 2.340 P = 2.79E −71 9 Sun Brain/2006 [36]
Glioblastoma 2.24 P = 10E −15 81
VEGFA
Malignant glioma, NOS 210.500 P = 0.005 10 Pomeroy Brain/2002 [28]
Glioblastoma 9.415 P = 1.03E −6 26 Bredel Brain 2/2005 [39]
Glioblastoma 8.624 P = 1.51E −19 81 Sun Brain/2006 [36]
Anaplastic astrocytoma 2.008 P = 0.003 19
Pilocytic astrocytoma 7.651 P = 0.001 8 Guttman
Glioblastoma 5.228 P = 5.10E −4 30 Liang Brain/2005 [40]
Glioblastoma 4.998 P = 5.28E −8 27 Shai Brain/2003 [37]
Anaplastic oligoastrocytoma 4.438 P = 0.003 23 French Brain/2005 [27]
Anaplastic oligodendroglioma 3.121 P = 7.92E −64
MMP2
Glioblastoma 6.426 P = 5.41E −4 27 Bredel Brain 2/2005 [39]
Glioblastoma 4.537 P = 0.003 30 Liang Brain/2005 [40]
Pilocytic astrocytoma 4.030 P = 0.001 8 Gutmann Brain/2002 [41]
Glioblastoma 3.548 P = 7.99E −16 81
Sun Brain/2006 [36] Diﬀuse astrocytoma 3.342 P = 0.010 19
Anaplastic astrocytoma 2.697 P = 1.33E −57
Anaplastic oligodendroglioma 2.980 P = 1.29E −72 3 French Brain/2005 [27]
Anaplastic oligoastrocytom 2.214 P = 0.006 48 Journal of Oncology
Table 2: Continued.
Gene Brain tumour type Upregulation fold/normal P Value Patients’ number Study/year [REF]
NEDD9
Atypical teratoid/rhabdoid tumour 58.972 P = 0.008 5
Pomeroy Brain/2002 [28] Malignant glioma, NOS 17.133 P = 0.007 10
Classic medulloblastoma 7.818 P = 3.59E −84 6
Desmoplastic medulloblastoma 5.238 P = 0.003 14
Glioblastoma 2.330 P = 3.69E −7 25 Bredel Brain 2/2005 [39]
HIF1A
Oligodendroglioma 3.395 P = 0.007 3 Shai Brain/2003 [37]
Glioblastoma 2.660 P = 1.96E −10 27
Anaplastic oligoastrocytoma 3.101 P = 9.50E −44 French Brain/2005 [27]
Anaplastic oligodendroglioma 2.576 P = 4.35E −62 3
Glioblastoma 2.954 P = 5.21E −92 6
Bredel Brain 2/2005 [39]
Anaplastic oligodendroglioma 2.404 P = 4.78E −43
Oligodendroglioma 2.167 P = 0.003 5
Diﬀuse astrocytoma 2.115 P = 6.68E −5 7 Sun Brain/2006 [36]
Astrocytoma 2.057 P = 5.79E −4 45 Rickman Brain/2001 [38]
and in response to hypoxia inducible factor 1. This gene
list incorporated HIF1A, VEGFA, SOX4, SOX9, NEDD9,
CLO4A1, COL1A1, and other genes. The query included
S 6 K 1h a sb e e nd o n ei nb r a i na n dC N St u m o u r sv e r s u sn o r -
mal brain. We have observed that S6K1 is co-overexpressed
with known genes that are induced by hypoxia. Figure 3(a)
shows a heat map of coexpression proﬁle analysis of S6K1
and hypoxia-induced genes in Pomeroy brain study [28].
The analysis showed a signiﬁcant overexpression of S6K1
and hypoxia-induced genes in atypical Teratoid/Rhabdoid
Tumour compared to normal cerebellum (Figure 3(a)). To
extend the analysis to more studies we compared the
expression proﬁle of S6K1 and hypoxia-induced genes in 4
diﬀerent brain tumours comprising 3 independent studies
[27–29] (298 patients). Figure 3(b) shows the comparison of
S6K1 and hypoxia-induced genes expression proﬁle across 4
diﬀerent analyses. We noticed that VEGFA, HIF1A, SOX4,
SOX9, MMP2, TGFB1 genes are overexpressed together with
S6K1 in all 4 tumour types investigated.
Taken those results together, we indicate that S6K1
overexpression in brain tumours is associated with overex-
pression of hypoxia-induced genes and reﬂects a possible
connection between S6K1 and hypoxia in that tumour type.
4. Discussion
mTOR/S6K pathway plays an important role in normal
and cancer cell. Deregulation of this pathway is reported
in various cancers highlighting it as a possible target in
cancer. Data suggest that S6K1 is implicated in breast cancer.
S6K1 is encoded by the RPS6KB1 gene localized to the
chromosomal region 17q23. Region 17q23 is ampliﬁed in
several breast cancer cell lines and in about 30% of primary
tumours [44], whereas S6K1 is overexpressed in the majority
of breast cell lines and breast primary tumours with this
ampliﬁcation [45–48]. In brain and CNS tumours, there
is no data regarding the S6 kinases gene expression proﬁle
and gene ampliﬁcation. Using a rich source of publically
available cancer microarray data as the Oncomine database,
we investigated the gene expression of S6 kinases in diﬀerent
tumours. The overexpression of S6K1 in brain tumours
not S6K2 attracted our attention to a distinct role of this
homologue in brain tumours. We then surveyed the litera-
ture and found no gene expression analysis of S6 kinases in
brain tumours has been done. In this study, we interrogated
the oncomine database for S6K1 gene expression level and
its association patient’s clinical outcomes. Furthermore, we
investigated the gene expression proﬁle of hypoxia-induced
genes and their association with S6K1 gene expression.
Here, we show that S6K1 but not S6K2 is overexpressed
indiﬀerentbraintumoursasatypicalteratoidtumour,classic
medulloblastoma, glioblastoma, and anaplastic oligoastro-
cytoma compared to normal brain in cancer microarray
database; Oncomine (Figure 1). No reports indicated the
upregulationofS6K1inbraintumoursatthegeneexpression
level. S6K1 gene is known to be ampliﬁed in breast and
cervical cancer patients but no reports regarding its ampli-
ﬁcation in brain tumours have been identiﬁed. To test the
hypothesis if the overexpression of S6K1 mRNA could be
due to its gene ampliﬁcation, we investigated the oncomine
databaseandfoundonlytworecordsforS6Kcopynumberin
brain tumours. No signiﬁcant diﬀerence between S6K DNA
copy number in normal and brain tumour was detected in
the investigated datasets (data not shown). This excludes
the possibility of S6K1 gene ampliﬁcation and explains that
the gene expression upregulation involves upstream gene
transcription regulators that bind to S6K1 gene promoter
and enhance its expression. We also observed that the
overexpression of S6K1 in anaplastic oligoastrocytoma was
signiﬁcantly associated with patients’ poor survival statusJournal of Oncology 9
in 3 diﬀerent analyses, which could attract the attention
for S6K1 as a possible marker for prognosis in those brain
tumourtypes.Furthermore,wehaveobservedanassociation
of S6K1 gene overexpression and patients’ poor survival in
classic medulloblastoma when we analysed Pomeroy et al.
study [28] (supplementary Figure 1(a)).
Due to limited number of studies available on brain
tumours and CNS, extending the analysis to other tumours
types as glioblastoma retrieved only one study; Murat brain
study 2008 [43]. No signiﬁcant diﬀerence was observed
between the S6K1 expression levels in the patients’ survived
after 5 years and patients who died after the same period
(Supplementary Figure 2(a)).
Induction of angiogenic factors in tumours is a result for
hypoxicinduction.Thetumoursadaptthemselvestohypoxic
condition by upregulation of HIF1 gene transcription factor
which upregulates vascular endothelial growth factor VEGF
which is a crucial modulator of new blood vessels formation
in tumour. This pathway attracted many studies and is a tar-
get for new therapy. The critical role of the hypoxia response
network and HIF in cancer has resulted in it being viewed
as an ideal target for small molecule intervention (reviewed
in [49]). In this study, we investigated the expression proﬁle
of hypoxia-induced genes in oncomine cancer microarray
database using a literature deﬁned concept. We investigated
a list of genes that are known from literature to respond
to hypoxia; for example: HIF1, VEGFA, MMP2, SOX9,
SOX4, and NEDD9. We have found that all those genes are
signiﬁcantly overexpressed in diﬀerent brain tumour types
comparedto normal brain. Furthermore, we showed that the
overexpression of S6K1 is associated with the upregulation
of hypoxia-induced genes. mTOR/S6K pathway is linked
recently to hypoxia mechanism in cancers. Targeting hypoxia
andS6Kpathwaycouldbeausefultoolinbraintumoursand
better prognosis.
Overall, we report here the induction of S6K1 gene
expression in diﬀerent brain tumours compared to normal
brain.Thisoverexpressionpatternisassociatedwithpatient’s
poor survival and upregulation of hypoxic-induced genes.
These results highlight the possible role of S6K1 in brain
tumour progression and as an upstream regulator of hypoxic
response. This attracts a further investigation of reported
gene combination as a predictor for patients’ survival.
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